We've been working in partnership with GSK since 2013, and after 10 years, we have renewed our partnership commitment to help protect the health of children, with a focus on Nigeria and Ethiopia.
‘Zero dose’ children – those who have never had any routine vaccination – are the most likely to contract diseases like polio, measles and cholera. As vaccination rates drop, these preventable diseases are appearing in places where they haven’t been seen for decades, and can be life-threatening. Nowhere has this been felt more starkly than in Africa. The continent has the highest number of zero dose children in the world – 8.7 million. More than a third live in Nigeria and Ethiopia alone.
Over the next five years and with a new £15 million investment, GSK and Save the Children’s goal is to significantly increase the number of children receiving vaccinations in the areas where we’ll be working in Ethiopia and Nigeria. We will use our combined expertise and 10 years of experience working together to develop pilot and implement tailored approaches to reach zero dose children in diverse settings.
By working with communities, governments and partner organisations, and by sharing our findings on what works, we aim to make sure our solutions can be used by others and incorporated into national policy. And our robust research will help us advocate for more children around the world to receive vaccinations, so they stay healthy, happy and thriving.